

IN THE CLAIMS:

Please amend the claims as follows:

Claims 1-8 (**cancelled**).

Claim 9 (**currently amended**): A pharmaceutical composition comprising AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and one of 5-FU and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.

Claim 10 (**cancelled**).

Claim 11 (**original**): A pharmaceutical composition comprising AZD2171 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.

Claim 12 (**currently amended**): A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and one of:

- a) 5-FU;
- b) CPT-11; and
- c) 5-FU and CPT-11.

Claims 13-14 (**cancelled**).

Claim 15 (**currently amended**): A method for the treatment of a cancer in a warm-blooded animal in need thereof ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of one of:

- a) 5-FU;
- b) CPT-11; and
- c) 5-FU and CPT-11.

Claim 16 (**currently amended**): A method for the treatment of a cancer in a warm-blooded animal in need thereof ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of one of:

- a) 5-FU;
- b) CPT-11; and
- c) 5-FU and CPT-11;

and before, after or simultaneously with an effective amount of ionising radiation.

Claim 17 (**currently amended**): The A-method according to claim 15 or claim 16 wherein AZD2171 is in a form of the free base.

Claim 18 (**currently amended**): A method for the treatment of a cancer in a warm-blooded animal in need thereof ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 maleate salt, before, after or simultaneously with an effective amount of

5-FU and CPT-11.

Claim 19 (**cancelled**).

Claim 20 (**new**): The method according to any one of claims 15, 16 and 18 wherein the cancer is a solid tumour cancer.

Claim 21 (**new**): The method according to any one of claims 15, 16 and 18 wherein the cancer is colorectal cancer.

Claim 22 (**new**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of one of:

- a) 5-FU;

- b) CPT-11; and
- c) 5-FU and CPT-11.

Claim 23 (**new**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 maleate salt before, after or simultaneously with an effective amount of 5-FU and CPT-11.